Minimal residual disease (MRD) detection in colorectal cancer (CRC) using a plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay

被引：1
|
作者：
Parikh, A. [1 ]
van Seventer, E. [2 ]
Boland, G. [1 ]
Siravegna, G. [1 ]
Hartwig, A. [3 ]
Jaimovich, A. [4 ]
Raymond, V. M. [5 ]
Talasaz, A. [6 ]
Corcoran, R. B. [7 ]
机构：
[1] Massachusetts Gen Hosp, Hematol Oncol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[3] Guardant Hlth Inc, Res & Dev, Redwood City, CA USA
[4] Guardant Hlth Inc, Bioinformat, Redwood City, CA USA
[5] Guardant Hlth Inc, Med Affairs, Redwood City, CA USA
[6] Guardant Hlth Inc, Redwood City, CA USA
[7] MGH Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.530
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
419P
引用
收藏
页码：S419 / S419
页数：1
相关论文
共 50 条
  • [21] Circulating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay
    Vasconcelos, Joao Paulo Solar
    Titmuss, Emma
    Navarro, Fabio
    Abbott, Charles
    Chia, Brendan
    Topham, James T.
    Ladua, Gale
    Krishnan, Tharani
    Hegebarth, Daniela
    Lim, Howard J.
    Gill, Karamjit
    Gill, Sharlene
    Brown, Carl J.
    Ghuman, Amandeep
    Meneghetti, Adam
    Renouf, Daniel John
    Schaeffer, David F.
    Chen, Richard
    Boyle, Sean Michael
    Loree, Jonathan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Combined genomic and epigenomic assessment of cell-free circulating tumor DNA (ctDNA) improves assay sensitivity in early-stage colorectal cancer (CRC)
    Kim, Seung-Tae
    Raymond, Victoria M.
    Park, Joon Oh
    Zotenko, Elena
    Park, Young Suk
    Schultz, Matthew
    Kang, Won Ki
    Westesson, Oscar
    Kim, Hee-Cheol
    He, Yupeng
    Odegaard, Justin I.
    Mortimer, Stefanie A.
    Greenleaf, William J.
    Jaimovich, Ariel
    Lee, Jeeyun
    Talasaz, AmirAli
    CANCER RESEARCH, 2019, 79 (13)
  • [23] The application of circulating tumor DNA for minimal residual disease detection in colorectal cancer
    Chan, Hiu Ting
    Nagayama, Satoshi
    Chin, Yoon Ming
    Otaki, Masumi
    Hayashi, Rie
    Fukunaga, Yosuke
    Ueno, Masashi
    Nakamura, Yusuke
    Low, Siew-Kee
    CANCER SCIENCE, 2021, 112 : 526 - 526
  • [24] Longitudinal evaluation of circulating tumor DNA (ctDNA) as a prognostic biomarker to detect minimal residual disease (MRD) in testicular cancer
    Hassoun, Rebecca
    Ben-David, Reuben
    Sfakianos, John P.
    Laliotis, George
    Cary, Clint
    Masterson, Timothy A.
    Rivero-Hinojosa, Samuel
    Manage, Kevin
    Dutta, Punashi
    Tillu, Neeraja
    Cumarasamy, Shivaram
    King, Jennifer
    Rich, Jordan
    Rock, Adam
    Dorff, Tanya B.
    ElNaggar, Adam
    Liu, Minetta C.
    Einhorn, Lawrence H.
    Chehrazi-Raffle, Alex
    Adra, Nabil
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Multimodal circulating tumor DNA (ctDNA) colorectal neoplasia detection assay for asymptomatic and early-stage colorectal cancer (CRC).
    Lee, Jeeyun
    Kim, Hee C.
    Kim, Seung Tae
    He, Yupeng
    Sample, Paul
    Nakamura, Yoshiaki
    Raymond, Victoria M.
    Jaimovich, Ariel
    Talasaz, AmirAli
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] Performance characteristics of a tumor-informed circulating tumor DNA (ctDNA) minimal residual disease (MRD) assay in invasive bladder cancer in clinical practice.
    Mehler, Shoshana
    Guilbeau, Seth
    Somer, Shmuel
    Reed, Kevin
    Greene, Heather
    Vaena, Daniel A.
    Grothey, Axel
    Somer, Brad
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [27] CORRECT-MRD I: A clinical validation study to predict recurrence in stage II-III colorectal cancer (CRC) using a bespoke circulating tumor DNA (ctDNA) assay to detect molecular residual disease (MRD).
    Tsukada, Yuichiro
    Sagawa, Tamotsu
    Srinivasan, Gopalakrishnan
    Hubert, Ayala
    Purim, Ofer
    Semenisty, Valeriya
    Lo, Nangi
    Mondello, Giuseppe
    Gracian, Antonio Cubillo
    Marti, Tara
    Subramaniam, Somasundaram
    Palomares, Melanie R.
    Baehner, Frederick
    de Jong, Floris A.
    Kerr, David James
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : TPS98 - TPS98
  • [28] Monitoring minimal residual disease (MRD) by KRAS mutation burden in urinary or plasma circulating tumor (ct) DNA in colorectal cancer (CRC) patients with resectable liver metastases
    Vibat, Cecile Rose T.
    Melnikova, Vlada
    Minarik, Marek
    Belsanova, Barbora
    Hancock, Saege
    Hassaine, Latifa
    Samuelsz, Errin
    Lu, Timothy T.
    Erlander, Mark G.
    Benesova, Lucie
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Impact of postoperative integrated genomic and epigenomic signatures of circulating tumor DNA (ctDNA) on recurrence in resected colorectal cancer: Initial report of a prospective ctDNA monitoring study COSMOS-CRC-01
    Tsukada, Yuichiro
    Matsuhashi, Nobuhisa
    Murano, Tatsuro
    Shiozawa, Manabu
    Kato, Takeshi
    Oki, Eiji
    Goto, Masahiro
    Kagawa, Yoshinori
    Kanazawa, Akiyoshi
    Ohta, Takashi
    Ouchi, Akira
    Bando, Hideaki
    Zuo, Xiaotong
    Parsana, Princy
    Price, Kristin Sedgwick
    Ikematsu, Hiroaki
    Yoshino, Takayuki
    Nakamura, Yoshiaki
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [30] A clinical validation study to predict recurrence in stage II-III colorectal cancer (CRC) using a bespoke circulating tumor DNA (ctDNA) assay to detect molecular residual disease (MRD): The CORRECT-MRD I study
    Srinivasan, G.
    Hubert, A.
    Purim, O.
    Semenisty, V.
    Lo, N.
    Tsukada, Y.
    Mondello, G.
    Cubillo, A.
    Subramaniam, S.
    Palomares, M. R.
    Baehner, R. F. L.
    De Jong, F.
    Kerr, D. J.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S69 - S70
12345